文献速递妇科肿瘤

靶向间皮素载紫杉醇相变纳米粒用于卵巢癌超声分子成像与治疗的初步研究

[Preliminary study of mesothelin-loaded paclitaxel nanoparticles for ultrasound molecular imaging and treatment of ovarian cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

采用薄膜水化法制备载紫杉醇相变纳米粒PTX-NPs,经生物素-亲和素法连接抗间皮素抗体制得Ab-PTX-NPs,在卵巢癌SKOV3细胞与BALB/c裸鼠模型中评价其靶向性、超声成像能力、杀伤效果及生物安全性,结果显示Ab-PTX-NPs具有良好靶向杀伤作用并降低紫杉醇毒性。

要点

  • Ab-PTX-NPs粒径(690.46±28.75)nm,紫杉醇包封率(88.2±4.4)%,载药量(27.3±0.9)%。
  • 6 W为低强度聚焦超声诱导Ab-PTX-NPs相变的最佳激发功率。
  • Ab-PTX-NPs组SKOV3细胞凋亡和坏死率达79.6%。

核心结论

  • 成功制备的Ab-PTX-NPs具有良好的卵巢癌靶向能力和杀伤效果,并有效降低紫杉醇的毒性。

研究设计与样本

  • 制备载紫杉醇相变纳米粒PTX-NPs及靶向间皮素载紫杉醇相变纳米粒Ab-PTX-NPs,并对其理化性质进行表征。
  • 在卵巢癌SKOV3细胞中检测Ab-PTX-NPs的靶向能力及体外杀伤能力。
  • 构建BALB/c裸鼠卵巢癌模型,观察Ab-PTX-NPs体内分布及对血生化和重要脏器的影响。

主要发现

  • Ab-PTX-NPs的Zeta电位为-(8.37±2.71)mV,直径为(690.46±28.75)nm,对紫杉醇包封率为(88.2±4.4)%,载药量为(27.3±0.9)%,抗间皮素抗体与PTX-NPs的连接率为(94.9±2.8)%。
  • 低强度聚焦超声可成功诱导Ab-PTX-NPs相变实现超声造影成像,6 W为最佳激发功率。
  • Ab-PTX-NPs组SKOV3细胞凋亡和坏死率达79.6%。
  • 活体成像显示Ab-PTX-NPs组裸鼠肿瘤部位荧光强度明显高于PTX-NPs组。
  • Ab-PTX-NPs给药15 d后裸鼠血清天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、肌酸激酶、低密度脂蛋白、血肌酐和尿素氮浓度与PBS组、对照纳米粒组和PTX-NPs组无明显差异,心、肝、脾、肺和肾等脏器保持完整,肉眼和镜下所见与PBS组、对照纳米粒组和PTX-NPs组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To prepare mesothelin-loaded paclitaxel (PTX) phase change nanoparticles and evaluate their targeting effect and therapeutic effect on ovarian cancer. Methods: PTX-loaded phase-change nanoparticles PTX-NPs were prepared by the thin-film hydration method, and targeted mesothelin-loaded PTX phase-change nanoparticles Ab-PTX-NPs were prepared by attaching anti-mesothelin antibody to the nanoparticles using the biotin-affinity method. Zeta potential and particle size were determined by applying a zeta potential and a particle size analyzer, and the encapsulation rate and the amount of drug loading of PTX was measured by applying a UV spectrophotometer. Flow cytometry was used to detect the connectivity of anti-mesothelin antibody with PTX-NPs. The phase transition of Ab-PTX-NPs was induced by low-power focused ultrasound, and its ultrasonography imaging was observed; laser scanning confocal microscopy and flow cytometry were used to detect the targeting ability of Ab-PTX-NPs on ovarian cancer SKOV3 cells. The targeting and killing ability of Ab-PTX-NPs on ovarian cancer SKOV3 cells was observed by in vitro targeting assay and apoptosis detection assay. The ovarian cancer model of BALB/c nude mice was constructed to observe the distribution of Ab-PTX-NPs in vivo as well as the effects on blood biochemistry and important organs of nude mice. Results: Ab-PTX-NPs were successfully prepared with a zeta potential of -(8.37±2.71) mV, a diameter of (690.46±28.75) nm, an encapsulation rate of (88.2±4.4)% for PTX, a drug loading capacity of (27.3±0.9)%, and a linkage rate of (94.9±2.8)% between anti-mesothelin antibody and PTX-NPs. Low-intensity focused ultrasound could successfully induce phase transition of Ab-PTX-NPs to realize ultrasonography imaging, and 6 W was the optimal excitation power for low-intensity focused ultrasound. Ab-PTX-NPs showed excellent targeting and killing ability to SKOV3 cells, and the apoptosis and necrosis rate of SKOV3 cells in the Ab-PTX-NPs group reached 79.6%. In vivo imaging showed that the fluorescence intensity at the tumor site of nude mice in the Ab-PTX-NPs group was significantly higher than that in the PTX-NPs group. Biosafety assay showed that 15 d after Ab-PTX-NPs administration, the serum aspartate aminotransferase, alanine aminotransferase, creatine kinase, low-density lipoprotein, blood creatinine, and urea nitrogen concentrations of nude mice were (174.163±20.596)U/L, (33.297±2.573)U/L, (1 959.978±72.212)U/L, (22.033±5.030)μmol/L, (0.393±0.058)mmol/L, and (26.405±4.957)mmol/L, which were not significantly different from those of the phosphate buffer solution (PBS) group, the NPs group, and the PTX-NPs group. The organs such as the heart, the liver, the spleen, the lungs and the kidneys remained intact, and what was seen by the naked eye and microscope was similar with those of the PBS group, NPs group and PTX-NPs group. Conclusion: Ab-PTX-NPs were successfully prepared, which had good ovarian cancer targeting ability and killing effect and effectively reduced the toxicity of PTX. 目的: 制备靶向间皮素载紫杉醇(PTX)相变纳米粒,评价其对卵巢癌的靶向效果和治疗作用。 方法: 采用薄膜水化法制备载PTX相变纳米粒PTX-NPs,利用生物素-亲和素法将抗间皮素抗体连接于纳米粒制备靶向间皮素载PTX相变纳米粒Ab-PTX-NPs。应用Zeta电位及粒度分析仪测定Zeta电位和粒径,应用紫外分光光度计测定PTX的包封率和载药量,采用流式细胞术检测抗间皮素抗体与PTX-NPs的连接率。以低功率聚焦超声诱导Ab-PTX-NPs相变,观察其超声造影成像情况;激光扫描共聚焦显微镜和流式检测Ab-PTX-NPs对卵巢癌SKOV3细胞靶向能力。通过体外靶向实验和凋亡检测实验观察Ab-PTX-NPs对卵巢癌SKOV3细胞的靶向杀伤能力。构建BALB/c裸鼠卵巢癌模型,观察Ab-PTX-NPs在体内的分布情况以及对裸鼠血生化、重要脏器的影响。 结果: 成功制备Ab-PTX-NPs,其Zeta电位为-(8.37±2.71)mV,直径为(690.46±28.75)nm,对PTX的包封率为(88.2±4.4)%,载药量为(27.3±0.9)%,抗间皮素抗体与PTX-NPs的连接率为(94.9±2.8)%。低强度聚焦超声可成功诱导Ab-PTX-NPs发生相变,实现超声造影成像,6 W为低强度聚焦超声的最佳激发功率。Ab-PTX-NPs对SKOV3细胞表现出优异的靶向作用和杀伤能力,Ab-PTX-NPs组SKOV3细胞的凋亡和坏死率达79.6%。活体成像可见,Ab-PTX-NPs组裸鼠肿瘤部位的荧光强度明显高于PTX-NPs组。生物安全性检测显示,Ab-PTX-NPs给药15 d后,裸鼠的血清天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、肌酸激酶、低密度脂蛋白、血肌酐和尿素氮浓度分别为(174.163±20.596)U/L、(33.297±2.573)U/L、(1 959.978±72.212)U/L、(22.033±5.030)μmol/L、(0.393±0.058)mmol/L和(26.405±4.957)mmol/L,与磷酸盐缓冲液(PBS)组、对照纳米粒组和PTX-NPs组无明显差异,心、肝、脾、肺和肾等脏器均保持完整,肉眼和镜下所见与PBS组、对照纳米粒组和PTX-NPs组相似。 结论: 成功制备了间皮素载PTX相变纳米粒Ab-PTX-NPs,其具有良好的卵巢癌靶向能力和杀伤效果,有效地降低了PTX的毒性。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Luo L, Wan YJ, Xu XZ, et al. [Preliminary study of mesothelin-loaded paclitaxel nanoparticles for ultrasound molecular imaging and treatment of ovarian cancer]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40375590. doi:10.3760/cma.j.cn112152-20240701-00270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。